Register for our free email digests:
Latest From Valneva SE
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.
This week’s roundup includes high-level appointments by Almirall, Hookipa Biotech and RXi Pharmaceuticals, in addition to CEO appointments by Karolinska Development and ReForm Biologics and various board announcements by companies including Faron and Redx.
This week’s roundup includes CEO appointments by Smart Matrix and IRX Therapeutics, with various senior level appointments by companies including Therachon, Mission Therapeutics and bluebird bio.
- Synthesis Technologies, Production Processes
- Large Molecule
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Valneva SE
- Senior Management
Thomas Lingelbach , Pres. & CEO
David Lawrence, CFO
Franck Grimaud, CBO
Wolfgang Bender, MD, PhD, CMO
- Contact Info
Phone: (33) 4 78 76 61 01
10-12 boulevard Marius Vivier Merle
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.